Business Strategy

MaxCyte currently has numerous relationships with leading biotech and pharmaceutical companies in the Americas and Asia that will provide near term revenues, participation in long term commercial opportunities and significant validation for MaxCyte's technology in the development of cell therapies. Companies developing cell therapies choose to partner with MaxCyte based upon its ability to create therapeutics that cannot otherwise be developed. MaxCyte provides these partners with the ability to effectively manipulate cell function with a process that provides safety, reproducibility/ consistency and scalability in a closed, cGMP process. In addition, the Company's existing FDA Master File and NIH RAC and Health Canada clearances allow partners to achieve rapid protocol approval and regulatory clearance. Each of these elements is required in the production of the cell therapy product in order to create a commercializable therapy. Limited by one or more of these elements, the Company's licensees have partnered with MaxCyte to move their programs forward. In addition to providing a source of non-dilutive financing and significant long term value, these relationships provide critical scientific and commercial validation.